KyungDong Pharm home

◆ KD PIPELINE summary

Information as of 2025.11


Innovative new drug pipeline
CategoryassignmentTherapeutic Area / TargetProgress stage
DiscoveryNon-clinicalPhase 1 clinical trialPhase 2 clinical trialPhase 3 clinical trialpermission
Innovative new drugKD2410immunotherapyComplete
BiologicsKDB2401Skin (atopy)Complete
KDB2501Skin (atopy)Complete
Incrementally Modified DrugsKDF1905urinary systemCompleteCompleteComplete
KDF1901 Antihypertensive AgentsCompleteCompleteCompleteComplete
KD2408obesityComplete
KD2502dyslipidemiaComplete
KD2503dry eye syndromeComplete
KD2406digestive systemComplete
KD2504diabetesComplete
KD2505diabetesComplete

KD2410

immunotherapy

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—

KDB2401

Skin (atopy)

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—

KDB2501

Skin (atopy)

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—

KDF1905

urinary system

Discovery
Complete
Non-clinical
Complete
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
Complete
permission
—

KDF1901

Antihypertensive Agents

Discovery
Complete
Non-clinical
Complete
Phase 1 clinical trial
Complete
Phase 2 clinical trial
—
Phase 3 clinical trial
Complete
permission
—

KD2408

obesity

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—

KD2502

dyslipidemia

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—

KD2503

dry eye syndrome

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—

KD2406

digestive system

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—

KD2504

diabetes

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—

KD2505

diabetes

Discovery
Complete
Non-clinical
—
Phase 1 clinical trial
—
Phase 2 clinical trial
—
Phase 3 clinical trial
—
permission
—
Innovative new drug pipeline
CategoryassignmentTherapeutic Area / TargetProgress stage
DiscoveryFormulation researchlivelypermission
Generic MedicinesKD2308digestive systemCompleteComplete
KD2303dyslipidemiaCompleteComplete
KD2407Antihypertensive AgentsCompleteComplete
KD2108dyslipidemiaCompleteComplete
KD2409GnRH agonistCompleteComplete
KD2501NSAIDsComplete
KD2102digestive systemCompleteCompleteCompleteComplete

KD2308

digestive system

Discovery
Complete
Formulation research
Complete
lively
—
permission
—

KD2303

dyslipidemia

Discovery
Complete
Formulation research
Complete
lively
—
permission
—

KD2407

Antihypertensive Agents

Discovery
Complete
Formulation research
Complete
lively
—
permission
—

KD2108

dyslipidemia

Discovery
Complete
Formulation research
Complete
lively
—
permission
—

KD2409

GnRH agonist

Discovery
Complete
Formulation research
Complete
lively
—
permission
—

KD2501

NSAIDs

Discovery
Complete
Formulation research
—
lively
—
permission
—

KD2102

digestive system

Discovery
Complete
Formulation research
Complete
lively
Complete
permission
Complete